We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Falco Selects PPD to Investigate Role of Biomarkers
News

Falco Selects PPD to Investigate Role of Biomarkers

Falco Selects PPD to Investigate Role of Biomarkers
News

Falco Selects PPD to Investigate Role of Biomarkers

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Falco Selects PPD to Investigate Role of Biomarkers"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Falco biosystems Ltd. and PPD, Inc. have announced that they have signed an agreement under which PPD's biomarker discovery sciences group will seek to discover and validate biomarkers that may lead to the development of a diagnostic test for renal cell carcinoma.

Under the terms of the agreement, PPD will apply its proprietary, integrated platform for proteomics, peptidomics and metabolomics to identify biomarkers for renal cell carcinoma using samples obtained from a clinical study designed to optimize discovery of useful biomarkers for renal cell carcinoma.

PPD will own any intellectual property derived from these analyses, and Falco will receive an exclusive license to use such intellectual property in specified countries.

PPD's technology allows for the identification of biomarkers that may have a useful role in disease detection and in the evaluation of therapeutic response.

Advertisement